The aim of this study was to characterise the kinetics and durability of neutralizing antibody (Nab) response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the presence of hyperglycemia.
Robust neutralizing antibodies to SARS-CoV-2 develop and persist in subjects with diabetes and COVID-19 pneumonia / Dispinseri, S., Lampasona, V., Secchi, M., Cara, A., Bazzigaluppi, E., Negri, D., Brigatti, C., Pirillo, M.F., Marzinotto, I., Borghi, M., Rovere-Querini, P., Tresoldi, C., Ciceri, F., Scavini, M., Scarlatti, G., Piemonti, L.. - In: THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. - ISSN 0021-972X. - (2021). [Epub ahead of print] [10.1210/clinem/dgab055]
Robust neutralizing antibodies to SARS-CoV-2 develop and persist in subjects with diabetes and COVID-19 pneumonia
Marzinotto, Ilaria;Rovere-Querini, Patrizia;Ciceri, Fabio;Piemonti, Lorenzo
Ultimo
2021-01-01
Abstract
The aim of this study was to characterise the kinetics and durability of neutralizing antibody (Nab) response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the presence of hyperglycemia.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
